Cutting-edge artificial intelligence methods are rapidly advancing the field of immuno-oncology. Researchers have engineered synthetic ligands that activate the Notch signaling pathway to optimize T-cell immunotherapies. Concurrently, AI-designed immune proteins are being developed to enhance precision and speed in cancer targeting. These breakthroughs underscore AI's growing role in drug discovery and immunotherapy design, offering new therapeutic modalities and accelerated development timelines.